Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
253 Leser
Artikel bewerten:
(1)

Hakluyt: The Royal Marsden Cancer Charity Announces a New Trustee

LONDON, Sept. 10, 2021 /PRNewswire/ -- Varun Chandra, Managing Partner of global strategic advisory firm Hakluyt, has been appointed as a Trustee for The Royal Marsden Cancer Charity, which raises money solely for world-leading cancer centre The Royal Marsden.

Varun Chandra, Managing Partner, Hakluyt

The Charity supports the hospital by funding life-saving research, enhancing treatment and care, building modern patient environments and investing in state-of-the-art equipment.

Prior to joining Hakluyt in 2014, Varun worked in investment and merchant banking, advising on mergers and acquisitions, private equity investments, and business development. Initially trained at Lehman Brothers, he went on to help build a regulated advisory firm for former UK Prime Minister Tony Blair, where he was responsible for transactions typically involving sovereign wealth and emerging markets businesses.

He sits on various charitable and commercial boards, including Sesame Workshop, the world's leading early learning media platform, the Marylebone Cricket Club Foundation, the Royal Academy Trust, the Young Vic theatre, and the British Asian Trust.

He said: "Everyone at Hakluyt is extremely proud of our longstanding relationship with The Royal Marsden, which is justly admired all over the world for its groundbreaking research and for pioneering the very latest in cancer treatments. Several colleagues have benefited from treatment at The Royal Marsden, and it is an immense privilege to be joining The Royal Marsden Cancer Charity as a Trustee. I look forward to working with Sir Douglas Flint, a member of the Hakluyt International Advisory Board, with Charles Alexander and the other Trustees, and with Antonia Dalmahoy and her brilliant team, as they continue their pioneering work in healthcare innovation. In particular, I am excited to be supporting them in further defining The Royal Marsden Cancer Charity's strategy, and pursuing new partnerships both domestically and internationally."

Antonia Dalmahoy, Managing Director of The Royal Marsden Cancer Charity, said: "I'm absolutely delighted to welcome Varun as a Trustee. He brings a wealth of experience that will be invaluable as the Charity recovers from the impact of the pandemic and looks to form new partnerships. His passion and commitment to The Royal Marsden Cancer Charity will be of enormous benefit to The Royal Marsden as they to continue to save and improve the lives of people affected by cancer."

Notes to editor

For further information please contact Abby Samuel, Head of PR & Communications at The Royal Marsden and The Royal Marsden Cancer Charity abby.samuel@rmh.nhs.uk or 07555147760.

About The Royal Marsden Cancer Charity

At The Royal Marsden we deal with cancer every day, so we understand how valuable life is. And when people entrust their lives to us, they deserve the very best. That's why the pursuit of excellence lies at the heart of everything we do and why The Royal Marsden Cancer Charity exists.

Thanks to our supporters we continue to be there for everyone who needs us, raising money solely to support the hospital. We ensure our nurses, doctors and research teams can provide the very best care and develop life-saving treatments, which are used across the UK and around the world.

From funding state-of-the-art equipment and ground-breaking research, to creating the very best patient environments, we will never stop looking for ways to improve the lives of people affected by cancer.

The Royal Marsden Cancer Charity
For a future beyond cancer.

About Varun Chandra and Hakluyt

Hakluyt is a strategic advisory firm that works with corporate leaders and investors around the world on their most important commercial issues.

Varun Chandra joined Hakluyt in 2014 and was elected managing partner in 2019. Prior to Hakluyt, he worked in investment and merchant banking. He is also a trustee of the Royal Academy Trust and the Young Vic theatre, sits on the boards of Sesame Workshop, the MCC Foundation and IP Group, Inc, and is an impact director for Yaletown.

For more information on Hakluyt, please visit www.hakluytandco.com

Photo - https://mma.prnewswire.com/media/1612967/Varun_Chandra_Managing_Partner_Hakluyt.jpg

© 2021 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.